Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The cardiotonic agent amrinone does not increase anatomic infarct size.

C A Campbell, P M Mehta, J Wynne

    Journal of Cardiovascular Pharmacology
    |February 1, 1987
    PubMed
    Summary

    This study found amrinone did not alter infarct size in dogs after coronary artery occlusion and reperfusion. However, amrinone did improve hemodynamic function during the occlusion period.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Advances in Acute Ischemic Stroke Treatment: Current Status and Future Directions.

    AJNR. American journal of neuroradiology·2023
    Same author

    Bracing for infantile scoliosis: no sedation needed.

    Studies in health technology and informatics·2021
    Same author

    Measuring vision using innate behaviours in mice with intact and impaired retina function.

    Scientific reports·2019
    Same author

    Basic Principles of Solarium Treatment.

    The Indian medical gazette·2017
    Same author

    Measurement of Radiant Energy in Light Therapy.

    The Indian medical gazette·2017
    Same author

    Erythema Standard for Dose in Light.

    The Indian medical gazette·2017

    Area of Science:

    • Cardiovascular Physiology
    • Pharmacology
    • Ischemic Heart Disease Research

    Background:

    • Previous research indicated amrinone (a positive inotropic agent) may worsen myocardial ischemia during brief coronary artery occlusions.
    • The impact of amrinone on infarct size following prolonged coronary artery occlusion and reperfusion remained uninvestigated.

    Purpose of the Study:

    • To investigate the effect of amrinone on anatomic infarct size in a canine model of myocardial infarction.
    • To assess amrinone's influence on hemodynamic parameters during coronary artery occlusion and reperfusion.

    Main Methods:

    • Anesthetized, open-chest dogs underwent 3 hours of coronary artery occlusion followed by 3 hours of reperfusion.
    • Amrinone (1-mg/kg bolus + 6 mg/kg/h infusion) or saline was administered intravenously starting 30 minutes post-occlusion.

    Related Experiment Videos

  • Infarct size, area at risk, and hemodynamic variables (left ventricular end-diastolic pressure, dP/dt, heart rate) were measured.

    • Main Results:

    • Amrinone treatment did not significantly alter the area at risk or the percentage of the area at risk that developed infarction compared to controls.
    • Amrinone administration significantly increased left ventricular maximum +dP/dt and heart rate during coronary occlusion.
    • Both groups showed an increase in left ventricular end-diastolic pressure following coronary artery occlusion.

    Conclusions:

    • Amrinone does not reduce anatomic infarct size in this model of prolonged coronary artery occlusion and reperfusion.
    • Amrinone improves cardiac contractility and heart rate during the ischemic period, suggesting potential benefits in acute hemodynamic support.